Using METACAM in cats
Proven safe for use in cats

No clinically relevant adverse events observed

  • In a 3-day target animal safety study,1 METACAM 5 mg/mL Solution for Injection administered Sub-Q at doses up to 5 times the regular dose was tolerated clinically by cats
  • At 5X regular dose: signs typical of NSAID toxicity were observed
    • Loose feces and vomiting
    • Histological changes of the GI tract and kidneys
  • In a field study of 138 cats,1 the incidence of adverse events in the 72 cats receiving METACAM Solution for Injection were:
    • 12.5%: post-treatment anemia
    • 8.3%: post-treatment elevated serum blood urea nitrogen (BUN) levels
    • One cat had pain upon palpation of the injection site 24 hours after receiving METACAM injection

Important Safety Information

As a class, cyclo-oxygenase inhibitory NSAIDs may be associated with gastrointestinal, kidney, or liver side effects. Pets should be evaluated for pre-existing conditions and currently prescribed medications prior to treatment with METACAM. Anesthetic drugs may affect renal perfusion; approach concomitant use of anesthetics and NSAIDs cautiously. Use of parenteral fluids during surgery is recommended. Concurrent use of nephrotoxic medications should be carefully approached. Multiple injections or concurrent or follow up use with an NSAID (including METACAM) or corticosteroid should be avoided. If side effects occur, pet owners should contact their veterinarian. Please refer to the package insert for complete product information.

1. METACAM Freedom of Information Summary, Supplemental NADA 141–219.

METACAM is a registered trademark and FLEXIDOSE is a trademark Boehringer Ingelheim Vetmedica GmbH, licensed to Boehringer Ingelheim Vetmedica, Inc.
© 2013 Boehringer Ingelheim Vetmedica, Inc.